인쇄하기
취소

Celltrion’s Remsima & Samsung’s SB5 about to be launched in US and Europe

Published: 2016-08-17 11:33:27
Updated: 2016-08-17 11:33:59

Celltrion(CEO Jung-jin Seo) and Samsung Bioepis(CEO Han-seung Ko) got a step closer to pioneering the U.S. and European markets.

According to the industry concerned, a U.S. patent suit on a Celltrion’s Remicade biosimilar, ‘Remsima,’ will be ruled at a local time on the 16th.

If Celltrion wins, it will be launched on the 3rd of October in the U.S.

A source tells CEO Jung-jin Seo of Celltrion...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.